Fisiopharma Srl – FDA 483, Sep 27, 2019
Fisiopharma Srl, a sterile drug manufacturer in Palomonte, Italy, was cited for significant deficiencies across its quality systems during an FDA inspection. Observations included inadequate aseptic process validation, insufficient investigation of discrepancies, unvalidated test methods, and deficient contamination control systems. The firm also lacked proper production control procedures, quality control unit adherence, and annual product review processes, indicating a broad failure to ensure drug product quality and purity.
ID · 5643b808-20a9-4631-8308-dfc84478a328
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.